Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor + G-CSF mobilization safety study for autologous stem cell transplantation
NL-OMON32383Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2008
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of plerixafor and granulocyte colony-stimulating factor in multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Sanofi. Primary endpoints: Safety, Grade 3 and 4 adverse events and serious adverse events and 3 more. Started Dec 2008; status: active, not recruiting.
02
Drugs
plerixaforgranulocyte colony-stimulating factor
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON32383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32383.